Skip to main content

XOMA

Stock
Health Care
Biotechnology

Performance overview

XOMA Price
Price Chart

Forward-looking statistics

Beta
0.68
Risk
51.55%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Company info

SectorHealth Care
IndustryBiotechnology
Employees68
Market cap$279.9M

Fundamentals

Enterprise value$323.4M
Revenue$42.9M
Revenue per employee
Profit margin-6.66%
Debt to equity135.24

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.73
Dividend per share
Revenue per share$3.64
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth+0.5
Credit+6.1
Liquidity+0.0
Inflation-3.3
Commodities-2.2
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-57.36
Price to sales7.52
P/E Ratio-57.36
Enterprise Value to Revenue7.54
Price to book3.81

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend dayJanuary 3, 2025

News

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research (June 24, 2025)
Recap: XOMA Q2 Earnings

Shares of XOMA (NASDAQ:XOMA) were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 12.12% over the past year to ($0.29), which beat the estimate of ($0.35).

Benzinga (August 5, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free